Report Publication Announcement • Dec 7, 2017
Report Publication Announcement
Open in ViewerOpens in native device viewer
Marseille, France, December 7, 2017, 7:00 AM CET
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2018, which is set as follows:
| March 8, 2018: | Publication of 2017 financial statements, with management comments. The 2017 Reference Document and Financial Report (included in the Reference Document) will be released during the second quarter of 2018. |
||
|---|---|---|---|
| May 16, 2018: | Publication of revenue for 1Q2018, with management comments. | ||
| May 29, 2018: | Annual shareholders meeting in Marseille. | ||
| September 17, 2018: | Publication of financial statements as of June 30, 2018, with management comments. |
||
| November 15, 2018: | Publication of revenue for 3Q2018, with management comments. |
All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section (www.innatepharma.com/en/financials).
Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immunity.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells.
The Company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.
Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company.
Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
| ISIN code | FR0010331421 |
|---|---|
| Ticker code | IPH |
| LEI | 9695002Y8420ZB8HJE29 |
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Dr Markus Metzger / Jérôme Marino Investor relations
Tel.: +33 (0)4 30 30 30 30
Consilium Strategic Communications Mary-Jane Elliott / Jessica Hodgson Tel.: +44 (0)20 3709 5700 [email protected]
ATCG Press Marie Puvieux Mob: +33 (0)6 10 54 36 72 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.